261 related articles for article (PubMed ID: 31518043)
1. Structural perspectives on HIV-1 Vif and APOBEC3 restriction factor interactions.
Azimi FC; Lee JE
Protein Sci; 2020 Feb; 29(2):391-406. PubMed ID: 31518043
[TBL] [Abstract][Full Text] [Related]
2. The APOBEC3C crystal structure and the interface for HIV-1 Vif binding.
Kitamura S; Ode H; Nakashima M; Imahashi M; Naganawa Y; Kurosawa T; Yokomaku Y; Yamane T; Watanabe N; Suzuki A; Sugiura W; Iwatani Y
Nat Struct Mol Biol; 2012 Oct; 19(10):1005-10. PubMed ID: 23001005
[TBL] [Abstract][Full Text] [Related]
3. Identification of a Conserved Interface of Human Immunodeficiency Virus Type 1 and Feline Immunodeficiency Virus Vifs with Cullin 5.
Gu Q; Zhang Z; Gertzen CGW; Häussinger D; Gohlke H; Münk C
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263270
[TBL] [Abstract][Full Text] [Related]
4. APOBEC3 degradation is the primary function of HIV-1 Vif determining virion infectivity in the myeloid cell line THP-1.
Ikeda T; Shimizu R; Nasser H; Carpenter MA; Cheng AZ; Brown WL; Sauter D; Harris RS
mBio; 2023 Aug; 14(4):e0078223. PubMed ID: 37555667
[TBL] [Abstract][Full Text] [Related]
5. Fab-based inhibitors reveal ubiquitin independent functions for HIV Vif neutralization of APOBEC3 restriction factors.
Binning JM; Smith AM; Hultquist JF; Craik CS; Caretta Cartozo N; Campbell MG; Burton L; La Greca F; McGregor MJ; Ta HM; Bartholomeeusen K; Peterlin BM; Krogan NJ; Sevillano N; Cheng Y; Gross JD
PLoS Pathog; 2018 Jan; 14(1):e1006830. PubMed ID: 29304101
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 and HIV-2 Vif interact with human APOBEC3 proteins using completely different determinants.
Smith JL; Izumi T; Borbet TC; Hagedorn AN; Pathak VK
J Virol; 2014 Sep; 88(17):9893-908. PubMed ID: 24942576
[TBL] [Abstract][Full Text] [Related]
7. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
He Z; Zhang W; Chen G; Xu R; Yu XF
J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467
[TBL] [Abstract][Full Text] [Related]
8. Structural determinants of HIV-1 Vif susceptibility and DNA binding in APOBEC3F.
Siu KK; Sultana A; Azimi FC; Lee JE
Nat Commun; 2013; 4():2593. PubMed ID: 24185281
[TBL] [Abstract][Full Text] [Related]
9. T-cell differentiation factor CBF-β regulates HIV-1 Vif-mediated evasion of host restriction.
Zhang W; Du J; Evans SL; Yu Y; Yu XF
Nature; 2011 Dec; 481(7381):376-9. PubMed ID: 22190036
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
[TBL] [Abstract][Full Text] [Related]
11. Maedi-visna virus Vif protein uses motifs distinct from HIV-1 Vif to bind zinc and the cofactor required for A3 degradation.
Knecht KM; Hu Y; Rubene D; Cook M; Ziegler SJ; Jónsson SR; Xiong Y
J Biol Chem; 2021; 296():100045. PubMed ID: 33465707
[TBL] [Abstract][Full Text] [Related]
12. Determinants of FIV and HIV Vif sensitivity of feline APOBEC3 restriction factors.
Zhang Z; Gu Q; Jaguva Vasudevan AA; Hain A; Kloke BP; Hasheminasab S; Mulnaes D; Sato K; Cichutek K; Häussinger D; Bravo IG; Smits SH; Gohlke H; Münk C
Retrovirology; 2016 Jul; 13(1):46. PubMed ID: 27368163
[TBL] [Abstract][Full Text] [Related]
13. A novel HIV-1 inhibitor that blocks viral replication and rescues APOBEC3s by interrupting vif/CBFβ interaction.
Duan S; Wang S; Song Y; Gao N; Meng L; Gai Y; Zhang Y; Wang S; Wang C; Yu B; Wu J; Yu X
J Biol Chem; 2020 Oct; 295(43):14592-14605. PubMed ID: 32817167
[TBL] [Abstract][Full Text] [Related]
14. Structural insights for HIV-1 therapeutic strategies targeting Vif.
Salter JD; Morales GA; Smith HC
Trends Biochem Sci; 2014 Sep; 39(9):373-80. PubMed ID: 25124760
[TBL] [Abstract][Full Text] [Related]
15. Vif Proteins from Diverse Human Immunodeficiency Virus/Simian Immunodeficiency Virus Lineages Have Distinct Binding Sites in A3C.
Zhang Z; Gu Q; Jaguva Vasudevan AA; Jeyaraj M; Schmidt S; Zielonka J; Perković M; Heckel JO; Cichutek K; Häussinger D; Smits SHJ; Münk C
J Virol; 2016 Nov; 90(22):10193-10208. PubMed ID: 27581978
[TBL] [Abstract][Full Text] [Related]
16. Cellular requirements for bovine immunodeficiency virus Vif-mediated inactivation of bovine APOBEC3 proteins.
Zhang W; Wang H; Li Z; Liu X; Liu G; Harris RS; Yu XF
J Virol; 2014 Nov; 88(21):12528-40. PubMed ID: 25142583
[TBL] [Abstract][Full Text] [Related]
17. Multifaceted HIV-1 Vif interactions with human E3 ubiquitin ligase and APOBEC3s.
Hu Y; Knecht KM; Shen Q; Xiong Y
FEBS J; 2021 Jun; 288(11):3407-3417. PubMed ID: 32893454
[TBL] [Abstract][Full Text] [Related]
18. CBFβ stabilizes HIV Vif to counteract APOBEC3 at the expense of RUNX1 target gene expression.
Kim DY; Kwon E; Hartley PD; Crosby DC; Mann S; Krogan NJ; Gross JD
Mol Cell; 2013 Feb; 49(4):632-44. PubMed ID: 23333304
[TBL] [Abstract][Full Text] [Related]
19. Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all.
Desimmie BA; Delviks-Frankenberrry KA; Burdick RC; Qi D; Izumi T; Pathak VK
J Mol Biol; 2014 Mar; 426(6):1220-45. PubMed ID: 24189052
[TBL] [Abstract][Full Text] [Related]
20. Structure-guided analysis of the human APOBEC3-HIV restrictome.
Aydin H; Taylor MW; Lee JE
Structure; 2014 May; 22(5):668-84. PubMed ID: 24657093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
